186 related articles for article (PubMed ID: 1938685)
21. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
Acar N; Diri MC; Türkyilmaz FR
Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
[TBL] [Abstract][Full Text] [Related]
22. Beta-lactamase evaluation of the amoxycillin-clavulanate association.
Novelli A; Reali EF; Fallani S; Periti P
Drugs Exp Clin Res; 1989; 15(4):151-4. PubMed ID: 2505995
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility-resistance patterns of bacterial isolates from burn patients to augmentin and timentin.
Holder IA; Vanderpool L; Wesselman J
J Burn Care Rehabil; 1985; 6(4):331-4. PubMed ID: 3879938
[No Abstract] [Full Text] [Related]
24. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole.
Jacobs MR; Spangler SK; Appelbaum PC
Eur J Clin Microbiol Infect Dis; 1990 Jun; 9(6):417-21. PubMed ID: 2387295
[TBL] [Abstract][Full Text] [Related]
26. Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.
Thomson CJ; Amyes SG
Epidemiol Infect; 1993 Feb; 110(1):117-25. PubMed ID: 8432315
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
Marre R; Schulz E
Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383
[TBL] [Abstract][Full Text] [Related]
28. Hyperproduction of TEM-1 beta-lactamase by Escherichia coli strains.
Page JW; Farmer TH; Elson SW
J Antimicrob Chemother; 1989 Jan; 23(1):160-1. PubMed ID: 2663805
[No Abstract] [Full Text] [Related]
29. Clavulanate-potentiated amoxycillin: in vitro antibacterial activity and oral bioavailability in calves.
Soback S; Bor A; Kurtz B; Paz R; Ziv G
J Vet Pharmacol Ther; 1987 Jun; 10(2):105-13. PubMed ID: 3302313
[TBL] [Abstract][Full Text] [Related]
30. A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.
Rolinson GN
J Chemother; 1994 Oct; 6(5):283-318. PubMed ID: 7861195
[TBL] [Abstract][Full Text] [Related]
31. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
Zhou XY; Bordon F; Sirot D; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1994 May; 38(5):1085-9. PubMed ID: 8067742
[TBL] [Abstract][Full Text] [Related]
32. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
33. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Thomson CJ; Amyes SG
J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
[TBL] [Abstract][Full Text] [Related]
34. Clavulanate-potentiated amoxycillin: activity in vitro and bioavailability in the dog.
Bywater RJ; Palmer GH; Buswell JF; Stanton A
Vet Rec; 1985 Jan; 116(2):33-6. PubMed ID: 3871985
[TBL] [Abstract][Full Text] [Related]
35. Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.
Kaye KS; Gold HS; Schwaber MJ; Venkataraman L; Qi Y; De Girolami PC; Samore MH; Anderson G; Rasheed JK; Tenover FC
Antimicrob Agents Chemother; 2004 May; 48(5):1520-5. PubMed ID: 15105100
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain).
Pérez-Moreno MO; Pérez-Moreno M; Carulla M; Rubio C; Jardí AM; Zaragoza J
Clin Microbiol Infect; 2004 Mar; 10(3):234-41. PubMed ID: 15008945
[TBL] [Abstract][Full Text] [Related]
37. In vitro antibacterial activities of ticarcillin alone and ticarcillin plus clavulanic acid against beta-lactamase producing and non-producing microorganisms.
Hsueh PR; Chang SC; Chen YC; Hsu LY; Luh KT; Hsieh WC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Aug; 25(3):149-59. PubMed ID: 1342000
[TBL] [Abstract][Full Text] [Related]
38. β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.
Ding J; Ma X; Chen Z; Feng K
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):532-3. PubMed ID: 23726651
[TBL] [Abstract][Full Text] [Related]
39. Amoxycillin/clavulanate resistant Escherichia coli.
Williams H; King A; Shannon K; Phillips I
Lancet; 1988 Feb; 1(8580):304-5. PubMed ID: 2893121
[No Abstract] [Full Text] [Related]
40. Efficacy of clavulanate-potentiated antibiotics against Bacteroides species and artificially associated cultures of aerobes and anaerobes.
Werner H; Heizmann WR; Freuer G; Mitinis N; Heilmann F
J Antimicrob Chemother; 1989 Nov; 24 Suppl B():55-61. PubMed ID: 2606820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
